

flawco
presents

RET INNOVATE

2026





MediNect is a preclinical contract research organisation (CRO) specialising in ophthalmology and translational eye research. Headquartered in Belfast, Northern Ireland, MediNect combines academic depth with commercial agility to

accelerate the development of innovative therapies for retinal diseases.

Our Expertise

MediNect provides a full spectrum of preclinical retinal disease services, including:

- *In vivo* efficacy and pharmacology in:
 - wetAMD
 - dryAMD
 - Inherited Retinal Diseases,
 - Diabetic Macular Oedema
 - Retinopathy of Prematurity
 - Retinal Vein Occlusion
 - Diabetic Retinopathy
 - Subretinal Fibrosis
 - Glaucoma
 - Uveitis (coming in 2026)
- Rodent and Rabbit pharmacokinetic (PK) and pharmacodynamic (PD) assessments across ocular compartments.
- Advanced 2D & 3D *in vitro* retinal and RPE models to complement *in vivo* studies for early screening and mechanistic understanding.
- Integration of mechanistic insights and biomarker discovery to support translational decision-making.
- Zebrafish drug screening (New for 2026)

Facilities and Capabilities

- Specialised laboratories for rodent and rabbit ocular studies.
- State-of-the-art imaging, histology, flow cytometry and molecular biology suites.
- Validated ocular PK/PD workflows supporting formulation and dose optimisation.
- Partnerships providing access to advanced analytical platforms for bioanalysis and multiomics.



Coming 2026



Ask about our special academic rates



MediNect Bioservices Ltd

☎ +44 28 960 05459

🌐 www.medinet.co.uk

✉ enquiries@medinet.co.uk



Schedule

DAY 1 FLOW

THURSDAY 13TH NOVEMBER

8:30AM

**REGISTRATION +
NETWORKING SCENES**

Registration

9:00AM

WELCOME + OPENING

Tunde Peto

Opening remarks from clinical KOL

9:15AM - 9.45AM

INTRO

James Bojdo and Chris McCabe

From Market to Bench. A reverse engineered approach to innovation.

9:15AM

**SESSION 1
PRECLINICAL RESEARCH:
DESIGNING WITH
PURPOSE**

**Alan Stitt, Chair of Ophthalmology, QUB
Kevin Harkin, Head of Ophthalmology, Medinect**

Strategies for ensuring translational relevance from the outset. Model selection, species choice, and study endpoints aligned to the different audiences.

11:00AM

COFFEE BREAK

A chance to network with colleagues and speakers.

11:20 AM

**SESSION 2
PRECLINICAL RESEARCH:
DESIGNING WITH
PURPOSE II**

Tine Van Bergen, OcuRes Consult

[A data package for smooth clinical progression:](#)
Designing robust, reproducible studies that meet regulatory and investor expectations. .

12:15 PM

**SESSION 3
REGULATORY PATHWAY
FOR RETINAL
THERAPEUTICS**

Stephen Liggett & Tine Van Bergen

Regulatory routes for retinal disease therapeutics
Key agency expectations, submission strategies, and approval timelines.



**12.45-1.45
LUNCH**

Network with speakers and fellow participants and discuss key innovation challenges.

**1.45-2.45 PM
SESSION 4
INTELLECTUAL PROPERTY**

Tim Belcher, Partner at EIP
[IP milestones from discovery to market: Strategies for building defensible, value-driving patent portfolios.](#)

**2.45-3.45PM
SESSION 5
PITCHING PERFECT**

Claire Gelfman, CMG Consulting-Retina Focus - online
Pitching to get Investor attention

**3.45-3.50PM
COFFEE BREAK**

Pick up Coffee

**3.50PM- 4.30PM
SESSION 6
UPS & DOWNS OF
BIOTECH WITH COFFEE**

Andy Osbourne, VP Preclinical, Ikarovec
Diary of an Academic through to Biotech
Informal chat with Q&As about working in a start-up biotech and exiting.

**4.30PM
FIRST DAY WRAP UP**

[Session wrap up - heading to the onsite bar](#)

**6:30 PM
DRINKS/DINNER
RECEPTION**



In collaboration with EVICR.net.
Join us for an evening reception with attendees of this years EVICR.net conference to meet clinicians that will play a critical role in your journey to clinic.
MALONE LODGE



DAY 2 FLOW

FRIDAY 14TH NOVEMBER

8:30AM

**REFLECTIONS, RECAP
AND REFRESHMENTS**

Regroup with participants and speakers

9:00AM

**SESSION 1
TARGET PRODUCT
PROFILE WORKSHOP**

Tine Van Bergen, Ocures Consult

Exercise: Developing a TPP framework: Target Product Profile as a strategic roadmap: Key components and methods for shaping a competitive product vision.

10:00AM

**SESSION 2
INVESTABLE STARTUP**

Luis Santana Diaz, LSDH Strategy

The Architecture of an Investable Startup

11:00AM- 11.15AM

COFFEE BREAK

COFFEE BREAK

11:15 AM

**SESSION 3
INVESTOR RELATIONS
AND DUE DILLIGENCE**

Jaspreet Grewal, Axial Bridge

Insights and expectation from investors

12.15 PM - 12.45PM

FIRESIDE CHAT

Global innovation landscape and investor insights

- **Jaspreet Grewal**, Founder, Axial Bridge
- **Paul Ryb**, Partner, Outcome Capital
- **Alan Stitt**, Editor-in-Chief - Progress in Retinal and Eye Research

12.45PM- 1.45PM

LUNCH

Lunch



1.45 PM - 2.15PM
SESSION 4
MARKET ACCESS I

Chris McCabe
[Affordable and sustainable Health Care - A challenge and opportunity for life science innovations.](#)

2.15-3.00 PM
SESSION 5
MARKET ACCESS II

Chris McCabe
[Starting with the end in mind - Early Health Technology Assessment and Value-Led Innovation](#)

3.00 PM- 3.45PM
SESSION 6
MARKET ACCESS III

Chris McCabe
[Headroom, value based pricing and indication selection](#)

3.45PM - 4.00PM
COFFEE BREAK

COFFEE BREAK

4:00PM- 4.30PM
SESSION 7
MARKET ACCESS IV

Chris McCabe
[Unpacking price from the pre-clinical end of the telescope](#)

4:30PM - 5.00PM
SESSION 8
MARKET ACCESS V

Chris McCabe
[Uncertainty and risk; research, investment and prices + Recap and Q&A.](#)

5:00PM
FINAL SESSION

Prof. Alan Stitt
What the future holds.
Looking at the the past, oresent and future



Notes



Notes



Notes



Notes



Notes



Notes



Notes



Notes



Notes



Notes



Notes



Notes



Notes



Notes



Notes



Notes



Notes

Notes



Notes



Notes



Notes



Notes



Notes



Notes



Notes



Notes



Notes



Notes



Notes



Notes



Notes



Brought to you by

flowco

Stay informed about

RETINNOVATE
2026

